{"pmid":32386444,"title":"Kidney transplantation and the lock-down effect.","text":["Kidney transplantation and the lock-down effect.","Kidney transplantation might not be considered a life-saving procedure as there are alternative forms of renal replacement, although it is superior in the long-term life expectancy and overall costs. During COVID-19 outbreak, we have to deal with the post-immunosuppression COVID-19 increased risk, a burden less prominent in the case of liver and heart transplant candidates, who eventually will die if not transplanted. Since kidney grafts can also be transplanted from a living donor, the suspended elective activity has had a major significant impact for this organ compared to the others.","Transpl Int","Bellini, Maria Irene","Tortorici, Francesco","Capogni, Marco","32386444"],"abstract":["Kidney transplantation might not be considered a life-saving procedure as there are alternative forms of renal replacement, although it is superior in the long-term life expectancy and overall costs. During COVID-19 outbreak, we have to deal with the post-immunosuppression COVID-19 increased risk, a burden less prominent in the case of liver and heart transplant candidates, who eventually will die if not transplanted. Since kidney grafts can also be transplanted from a living donor, the suspended elective activity has had a major significant impact for this organ compared to the others."],"journal":"Transpl Int","authors":["Bellini, Maria Irene","Tortorici, Francesco","Capogni, Marco"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32386444","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/tri.13639","topics":["Prevention"],"weight":1,"_version_":1666340102075318272,"score":9.490897,"similar":[{"pmid":32282982,"title":"Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","text":["Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices.","Am J Transplant","Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M","32282982"],"abstract":["COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices."],"journal":"Am J Transplant","authors":["Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282982","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15915","keywords":["clinical decision-making","epidemiology","guidelines","infectious agents - viral"],"locations":["US","US","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","remdesivir","tocilizumab","Azithromycin"],"topics":["Prevention"],"weight":1,"_version_":1666138491535228928,"score":242.73978},{"pmid":32367645,"title":"Response to \"The COVID-19 outbreak in Italy: initial implications for organ transplantation programs\".","text":["Response to \"The COVID-19 outbreak in Italy: initial implications for organ transplantation programs\".","I read the article on the overall reduction of Solid Organ Transplantation (SOT) activity in Italy, with growing concerns as also the National Regulatory Bodies (NRB) of Spain and the UK report substantial reduction of activity in their bulletins; currently, in the UK only five Kidney TxC are still operational. Importantly, another study reported in the US restricted SOT, with more than 70% of US Transplant Centres (TxC) having suspended Living Donor Kidney Transplantation (LDKT).","Am J Transplant","Cacciola, Roberto","32367645"],"abstract":["I read the article on the overall reduction of Solid Organ Transplantation (SOT) activity in Italy, with growing concerns as also the National Regulatory Bodies (NRB) of Spain and the UK report substantial reduction of activity in their bulletins; currently, in the UK only five Kidney TxC are still operational. Importantly, another study reported in the US restricted SOT, with more than 70% of US Transplant Centres (TxC) having suspended Living Donor Kidney Transplantation (LDKT)."],"journal":"Am J Transplant","authors":["Cacciola, Roberto"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367645","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/ajt.15968","locations":["Italy","Spain","GBR","GBR","US","Italy"],"countries":["United States","Italy","United Kingdom","Spain"],"countries_codes":["USA|United States","ITA|Italy","GBR|United Kingdom","ESP|Spain"],"weight":0,"_version_":1666138496293666816,"score":241.8491},{"pmid":32457133,"title":"The impact of the COVID-19 pandemic on renal transplantation in the UK.","text":["The impact of the COVID-19 pandemic on renal transplantation in the UK.","COVID-19 is impacting provision of renal transplantation in the UK with a reduction in clinical activity. Publicly available Renal Registry and NHS Blood and Transplant reports were analysed to model the number of missed transplant opportunities, waiting list size and change in dialysis population over a six-month period starting 5 March 2020. An estimated 1,670 kidney transplant opportunities may be lost, which will lead to 6,317 active patients on the kidney-alone waiting list, compared to 4,649 based on usual activity estimates. This will result in 1,324 additional patients on dialysis who would otherwise have been transplanted. COVID-19 will lead to a marked loss of transplant opportunities and a significantly larger national waiting list. The existing strain on dialysis capacity will be exacerbated as patients remain on dialysis as the only available form of renal replacement therapy. These findings will help inform policy and service specific strategies.","Clin Med (Lond)","Sharma, Videha","Shaw, Alex","Lowe, Marcus","Summers, Angela","van Dellen, David","Augustine, Titus","32457133"],"abstract":["COVID-19 is impacting provision of renal transplantation in the UK with a reduction in clinical activity. Publicly available Renal Registry and NHS Blood and Transplant reports were analysed to model the number of missed transplant opportunities, waiting list size and change in dialysis population over a six-month period starting 5 March 2020. An estimated 1,670 kidney transplant opportunities may be lost, which will lead to 6,317 active patients on the kidney-alone waiting list, compared to 4,649 based on usual activity estimates. This will result in 1,324 additional patients on dialysis who would otherwise have been transplanted. COVID-19 will lead to a marked loss of transplant opportunities and a significantly larger national waiting list. The existing strain on dialysis capacity will be exacerbated as patients remain on dialysis as the only available form of renal replacement therapy. These findings will help inform policy and service specific strategies."],"journal":"Clin Med (Lond)","authors":["Sharma, Videha","Shaw, Alex","Lowe, Marcus","Summers, Angela","van Dellen, David","Augustine, Titus"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32457133","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.7861/clinmed.2020-0183","keywords":["covid-19","nhs","kidney transplantation","renal insufficiency","renal replacement therapy"],"locations":["GBR","Transplant","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1667967699035095040,"score":232.45883},{"pmid":32354637,"pmcid":"PMC7142878","title":"COVID-19 infection in kidney transplant recipients.","text":["COVID-19 infection in kidney transplant recipients.","By 21 March 2020 infections related to the novel coronavirus SARS-CoV-2 had affected people from 177 countries and caused 11,252 reported deaths worldwide. Little is known about risk, presentation and outcomes of SARS-CoV-2 (COVID-19) infection in kidney transplantation recipients, who may be at high-risk due to long-term immunosuppression, comorbidity and residual chronic kidney disease. Whilst COVID-19 is predominantly a respiratory disease, in severe cases it can cause kidney and multi-organ failure. It is unknown if immunocompromised hosts are at higher risk of more severe systemic disease. Therefore, we report on seven cases of COVID-19 in kidney transplant recipients (median age 54 (range 45-69), three females, from a cohort of 2082 managed transplant follow-up patients) over a six-week period in three south London hospitals. Two of seven patients presented within three months of transplantation. Overall, two were managed on an out-patient basis, but the remaining five required hospital admission, four in intensive care units. All patients displayed respiratory symptoms and fever. Other common clinical features included hypoxia, chest crepitation, lymphopenia and high C-reactive protein. Very high D dimer, ferritin and troponin levels occurred in severe cases and likely prognostic. Immunosuppression was modified in six of seven patients. Three patients with severe disease were diabetic. During a three week follow up one patient recovered, and one patient died. Thus, our findings suggest COVID-19 infection in kidney transplant patients may be severe, requiring intensive care admission. The symptoms are predominantly respiratory and associated with fever. Most patients had their immunosuppression reduced and were treated with supportive therapy.","Kidney Int","Banerjee, Debasish","Popoola, Joyce","Shah, Sapna","Ster, Irina Chis","Quan, Virginia","Phanish, Mysore","32354637"],"abstract":["By 21 March 2020 infections related to the novel coronavirus SARS-CoV-2 had affected people from 177 countries and caused 11,252 reported deaths worldwide. Little is known about risk, presentation and outcomes of SARS-CoV-2 (COVID-19) infection in kidney transplantation recipients, who may be at high-risk due to long-term immunosuppression, comorbidity and residual chronic kidney disease. Whilst COVID-19 is predominantly a respiratory disease, in severe cases it can cause kidney and multi-organ failure. It is unknown if immunocompromised hosts are at higher risk of more severe systemic disease. Therefore, we report on seven cases of COVID-19 in kidney transplant recipients (median age 54 (range 45-69), three females, from a cohort of 2082 managed transplant follow-up patients) over a six-week period in three south London hospitals. Two of seven patients presented within three months of transplantation. Overall, two were managed on an out-patient basis, but the remaining five required hospital admission, four in intensive care units. All patients displayed respiratory symptoms and fever. Other common clinical features included hypoxia, chest crepitation, lymphopenia and high C-reactive protein. Very high D dimer, ferritin and troponin levels occurred in severe cases and likely prognostic. Immunosuppression was modified in six of seven patients. Three patients with severe disease were diabetic. During a three week follow up one patient recovered, and one patient died. Thus, our findings suggest COVID-19 infection in kidney transplant patients may be severe, requiring intensive care admission. The symptoms are predominantly respiratory and associated with fever. Most patients had their immunosuppression reduced and were treated with supportive therapy."],"journal":"Kidney Int","authors":["Banerjee, Debasish","Popoola, Joyce","Shah, Sapna","Ster, Irina Chis","Quan, Virginia","Phanish, Mysore"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354637","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.kint.2020.03.018","keywords":["covid-19","sars-cov-2 infection","immunosuppression","kidney transplantation"],"locations":["London","hypoxia","ferritin"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Case Report"],"weight":1,"_version_":1666138495195807744,"score":221.88632},{"pmid":32270388,"pmcid":"PMC7140588","title":"Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI).","text":["Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI).","The Liver Transplant Society of India (LTSI) has come up with guidelines for transplant centres across the country to deal with liver transplantation during this evolving pandemic of COVID-19 infection. The guidelines are applicable to both deceased donor as well as living donor liver transplants. In view of the rapidly changing situation of COVID-19 infection in India and worldwide, these guidelines will need to be updated according to the emerging data.","Hepatol Int","Saigal, Sanjiv","Gupta, Subash","Sudhindran, S","Goyal, Neerav","Rastogi, Amit","Jacob, Mathew","Raja, Kaiser","Ramamurthy, Anand","Asthana, Sonal","Dhiman, R K","Singh, Balbir","Perumalla, Rajasekhar","Malik, Ashish","Shanmugham, Naresh","Soin, Arvinder Singh","32270388"],"abstract":["The Liver Transplant Society of India (LTSI) has come up with guidelines for transplant centres across the country to deal with liver transplantation during this evolving pandemic of COVID-19 infection. The guidelines are applicable to both deceased donor as well as living donor liver transplants. In view of the rapidly changing situation of COVID-19 infection in India and worldwide, these guidelines will need to be updated according to the emerging data."],"journal":"Hepatol Int","authors":["Saigal, Sanjiv","Gupta, Subash","Sudhindran, S","Goyal, Neerav","Rastogi, Amit","Jacob, Mathew","Raja, Kaiser","Ramamurthy, Anand","Asthana, Sonal","Dhiman, R K","Singh, Balbir","Perumalla, Rajasekhar","Malik, Ashish","Shanmugham, Naresh","Soin, Arvinder Singh"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270388","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10041-1","locations":["India"],"countries":["India"],"countries_codes":["IND|India"],"topics":["Prevention"],"weight":1,"_version_":1666138491797372928,"score":220.01378}]}